Trafalis, D.T.; Sagredou, S.; Dalezis, P.; Voura, M.; Fountoulaki, S.; Nikoleousakos, N.; Almpanakis, K.; Deligiorgi, M.V.; Sarli, V.
Anticancer Activity of Triazolo-Thiadiazole Derivatives and Inhibition of AKT1 and AKT2 Activation. Pharmaceutics 2021, 13, 493.
https://doi.org/10.3390/pharmaceutics13040493
AMA Style
Trafalis DT, Sagredou S, Dalezis P, Voura M, Fountoulaki S, Nikoleousakos N, Almpanakis K, Deligiorgi MV, Sarli V.
Anticancer Activity of Triazolo-Thiadiazole Derivatives and Inhibition of AKT1 and AKT2 Activation. Pharmaceutics. 2021; 13(4):493.
https://doi.org/10.3390/pharmaceutics13040493
Chicago/Turabian Style
Trafalis, Dimitrios T., Sofia Sagredou, Panayiotis Dalezis, Maria Voura, Stella Fountoulaki, Nikolaos Nikoleousakos, Konstantinos Almpanakis, Maria V. Deligiorgi, and Vasiliki Sarli.
2021. "Anticancer Activity of Triazolo-Thiadiazole Derivatives and Inhibition of AKT1 and AKT2 Activation" Pharmaceutics 13, no. 4: 493.
https://doi.org/10.3390/pharmaceutics13040493
APA Style
Trafalis, D. T., Sagredou, S., Dalezis, P., Voura, M., Fountoulaki, S., Nikoleousakos, N., Almpanakis, K., Deligiorgi, M. V., & Sarli, V.
(2021). Anticancer Activity of Triazolo-Thiadiazole Derivatives and Inhibition of AKT1 and AKT2 Activation. Pharmaceutics, 13(4), 493.
https://doi.org/10.3390/pharmaceutics13040493